Vascular inflammation is a stronger predictor of residual cardiovascular risk than LDL cholesterol level among statin-treated patients. This finding from a large analysis of contemporary trials points to a potential new standard of care for atherosclerosis.
CLEAR Outcomes: Bempedoic Acid Reduces Cardiovascular Events in Statin-Intolerant Patients
A 14,000-patient trial has shown that LDL cholesterol reduction with the non-statin therapy translates to a lower rate of cardiovascular death, heart attack, stroke or revascularization.
Statin Intolerance and New Lipid-Lowering Treatments
This brief review shares a pragmatic road map for managing atherosclerosis in patients who cannot or will not take a statin. And it looks ahead to new statin alternatives on the horizon.
AHA 2018 Essentials: Dr. Steve Nissen on What Mattered Most (Video)
The veteran cardiologist reflects on the meeting’s biggest developments: the new cholesterol guideline, the VITAL trial of vitamin D, the REDUCE-IT controversy and a strikingly potent therapy for lowering Lp(a).
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Reducing Cholesterol Could Enhance T-Cell Cancer Immunotherapy
Cleveland Clinic researchers have demonstrated for the first time that lowering blood cholesterol levels could enhance the success of a specific type of T-cell immunotherapy in fighting cancer.
People with Diabetes May Be Missing Out on HDL Cardiovascular Protections
A Cleveland Clinic study reveals a mechanism that rapidly destroys high-density lipoprotein (HDL) in people with Type 2 diabetes, negating cardiovascular protections.
The Scourge of Statin Denial: A Portrait in Numbers (Infographic)
This infographic, derived from an editorial by Dr. Steven Nissen, outlines the causes, effects and high stakes of widespread misinformation about statins and cholesterol.
Diet and Pain
A patient’s healthy diet is fundamental to the success of pain management therapies. Here’s how sugar, processed carbohydrates, damaged fats and oils, and toxins can exacerbate chronic pain.
Distinctive Dozen: 12 Developments from 2016 Likely to Reshape Cardiovascular Practice
From heart benefits of diabetes drugs to leadless pacing to expanding populations for TAVR, 2016 was a dynamic year in cardiovascular care. Cleveland Clinic experts reflect on a dozen key developments.
Approval of First PCSK9 Inhibitor Marks New Era (Video)
FDA’s late-July approval of the first PCSK9 inhibitor is “a major event in cardiovascular medicine,” says Dr. Steve Nissen. Here’s his expert take on the place of this new cholesterol-lowering class in today’s practice.